IXICO posts strong H1 growth and bolsters cash for AI-driven neurology push

IXICO plc ( (GB:IXI) ) has issued an announcement.

IXICO reported a strong first half to 2026, with revenues expected to rise 23% to £3.9 million, driven by new contract wins, extensions and higher biomarker analysis volumes. The company also anticipates an improved gross margin of 53% and an expanded order book of £18.1 million, signalling robust future revenue visibility.

Despite ongoing investment in its Innovate, Lead, Scale growth strategy, IXICO expects to narrow its EBITDA loss to £0.5 million, reflecting operational leverage as activity scales. A recently completed £10 million capital raise is set to fund its Tech Bio strategy, deepening integration of the IXI™ platform with CROs, trial management systems and healthcare providers to enhance its market position.

Spark’s Take on IXI Stock

According to Spark, TipRanks’ AI Analyst, IXI is a Neutral.

The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.

To see Spark’s full report on IXI stock, click here.

More about IXICO plc

IXICO plc is a U.K.-listed neuroscience imaging and biomarker analytics specialist that operates as an imaging contract research organisation for neurological drug development. Using its proprietary AI-driven IXI™ platform, it supports global clinical trials in diseases such as Alzheimer’s, Huntington’s and Parkinson’s for leading pharma, biotechs and research consortia.

Average Trading Volume: 167,485

Technical Sentiment Signal: Sell

Current Market Cap: £6.83M

See more data about IXI stock on TipRanks’ Stock Analysis page.